Data as of Dec 12
| +0.56 / +4.38%|
The 7 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 12.00, with a high estimate of 17.00 and a low estimate of 4.00. The median estimate represents a -10.11% decrease from the last price of 13.35.
The current consensus among 8 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.